Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Aug 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain cells in the body, known as cancer-associated fibroblasts and myeloid-derived suppressor cells, might affect the ability of treatments like immunotherapy to work for patients with non-small cell lung cancer (NSCLC). Immunotherapy has been a breakthrough in cancer treatment, but not all patients respond well to it, and many eventually see their cancer return. The researchers want to understand how these immune-suppressing cells influence the effectiveness of treatments in patients with advanced lung cancer.

To participate in this study, you would need to be a patient diagnosed with lung cancer who has undergone surgery or received specific treatments between September 2018 and December 2021. However, if you have had chemotherapy, radiotherapy, or immunotherapy before surgery, or if you've been diagnosed with another type of cancer, you wouldn't be eligible. If you join the trial, researchers will collect samples from your tumor and analyze how these immune-suppressing cells affect cancer cells in the lab. This research aims to improve our understanding of why some patients don't respond to treatment and could help develop better therapies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • consecutive patients
• • lung carcinoma surgically treated by surgery only (objectives 1a and 2), or stage III lung carcinoma treated by concomitant radiochemotherapy followed by durvalumab (maintenance) treated between September 2018 and december 2021 (objective 1b)
• Exclusion Criteria:
• • patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)
• • patient with previous cancer